Replimune (REPL) stock plummeted 19% after the FDA again refused approval for melanoma drug RP1, citing insufficient evidence of effectiveness. The regulator stated the resubmission failed to change its initial conclusion. Replimune now has one year to withdraw or resubmit its application.